Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Afuresertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 12/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 5/20 | 1.00 |
| ▸ | AKT3 known ✓ | Q9Y243 | 5/20 | 1.00 |
| ▸ | PRKCA | P17252 | 3/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 3/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 2/20 | 1.00 |
| ▸ | PRKCB | P05771 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | PRKACB | P22694 | 2/20 | 1.00 |
| ▸ | PKN1 | Q16512 | 2/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | SGK1 | O00141 | 1/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | LATS1 | O95835 | 1/20 | 0.57 |
| ▸ | PRKCG | P05129 | 1/20 | 0.57 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.57 |
| ▸ | PRKCH | P24723 | 1/20 | 0.57 |
| ▸ | MARK3 | P27448 | 1/20 | 0.57 |
| ▸ | PRKCI | P41743 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afuresertib SCHEMBL29360487 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL15020961 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL29432553 | 0.99 | AKT1 (0.98) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL1364223 | 0.99 | AKT1 (0.98) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL23858298 | 0.99 | AKT1 (0.98) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL25062435 | 0.93 | AKT1 (0.87) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL1529676 | 0.92 | AKT1 (0.86) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL27791709 | 0.92 | AKT1 (0.86) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL1529379 | 0.92 | AKT1 (0.86) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL12143222 | 0.92 | AKT1 (0.84) | AKT1AKT2AKT3PRKCAROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 465 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4605376-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-08-27 | — | — | EP | claimed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| US-20250177352-A1 | COMBINATION TREATMENT FOR CANCER | LAEKNA LTD (CN) | 2025-06-05 | — | — | US | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| US-20250090514-A1 | METHOD OF TREATING CANCER | Laekna Limited (HK) | 2025-03-20 | — | — | US | claimed |
| CN-119013022-A | Combination therapy for cancer | 来凯有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024083802-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | VALDOSPAN GMBH (AT) | 2024-04-25 | — | — | WO | claimed |
| EP-4322949-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | RDP Pharma AG (CH) | 2024-02-21 | — | — | EP | claimed |
| CN-117580614-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| EP-2117523-B1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC (US) | 2014-06-25 | — | — | EP | claimed |
| US-8609711-B2 | Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride | GLAXOSMITHKLINE LLC (US) | 2013-12-17 | — | — | US | claimed |
| WO-2013160222-A1 | TREATMENT METHOD FOR STEROID RESPONSIVE DERMATOSES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-10-31 | — | — | WO | claimed |
| US-20130288984-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2013-10-31 | — | — | US | claimed |
| US-20130237554-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2013-09-12 | — | — | US | claimed |
| US-20130231346-A1 | METHODS OF TREATING CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-09-05 | — | — | US | claimed |
| US-20130072507-A1 | COMBINATION | GLAXOSMITHKLINE LLC | 2013-03-21 | — | — | US | claimed |
| US-20120258933-A1 | COMBINATION | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | claimed |
| US-8273782-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-09-25 | — | — | US | claimed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072507-A1 | COMBINATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLCO1B3, QDPR | AKT1 4047/4885AKT2 3607/4885AKT3 3678/4885 |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | AKT1 2/4885AKT2 1/4885AKT3 3/4885 |
| US-20130237554-A1 | COMBINATION | TPMT, NUP205, MGMT | AKT1 4196/4885AKT2 3171/4885AKT3 3911/4885 |
| US-20250177352-A1 | COMBINATION TREATMENT FOR CANCER | CD274, PDCD1LG2, PDCD1 | AKT1 3656/4885AKT2 1981/4885AKT3 1572/4885 |
| US-20130288984-A1 | COMBINATION | PSMB5, PSMA5, PSME3 | AKT1 3811/4885AKT2 3318/4885AKT3 3395/4885 |
| US-20250090514-A1 | METHOD OF TREATING CANCER | KLK3, ACP3, AR | AKT1 3033/4885AKT2 2799/4885AKT3 2766/4885 |
| US-20130231346-A1 | METHODS OF TREATING CANCER | KRAS, NRAS, HRAS | AKT1 58/4885AKT2 78/4885AKT3 106/4885 |
| US-20120258933-A1 | COMBINATION | PSMB5, PSMA5, PSME3 | AKT1 3811/4885AKT2 3318/4885AKT3 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.